Reports

Ideas That Generate Results

1. Analyst View

2. Research Methodology

3. Gene Therapy - An Introduction
    3.1 Classification of Gene Therapy Techniques
    3.2 Physical Methods of Gene Transfer
          3.2.1 Electroporation
          3.2.2 Hydrodynamic
          3.2.3 Microinjection
          3.2.4 Particle Bombardment
          3.2.5 Ultrasound-Mediated Transfection
    3.3 Vectors for Gene Therapy
          3.3.1 Viral Vectors
          3.3.2 Non Viral Vectors

4. Industry Overview
    4.1 Market Drivers
          4.1.1 Failure of Conventional Therapies to Treat Cancers
          4.1.2 Rising Focus to Accelerate Commercialization of Gene Therapy in Developed Nations
          4.1.3 Rising Incidence of Chronic and Life Threatening Diseases
          4.1.4 Growing Interest of Venture Capital Firms
    4.2 Market Restraints
          4.2.1 Stringent Regulatory Laws & Safety Concerns
          4.2.2 Pitfalls in Current Technique
          4.2.3 High Cost of the Gene Therapy Drugs
    4.3 Market Opportunities
          4.3.1 Approval of Gene Therapy Drug in Europe
          4.3.2 Gene Therapy for Hemophilia B Offers Significant Opportunity
    4.4 Industry Trends
          4.4.1 Gene Silencing: Gaining Momentum
          4.4.2 Advanced Therapies: Combining Gene Therapy and Stem Cell Technology
          4.4.3 Immunodeficiency Syndromes: The Focus of Gene Therapy
          4.4.4 Nanotechnology: Empowering Gene Therapy
          4.4.5 Gene Therapy: A New Hope to Treat Blindness
          4.4.6 Gene Therapy: Potential Cure for Cancer
    4.5 Winning Imperatives
          4.5.1 Investment in R&D Activities

5. Clinical Trial Assessment & Pipeline Analysis
     5.1 Clinical Trials
           5.1.1 By Geography
           5.1.2 By Indication
           5.1.3 By Gene Type
           5.1.4 By Vector
           5.1.5 By Clinical Trial Phase
    5.2 Pipeline Analysis

6. Gene Therapy Market - Regulatory Landscape & Reimbursement Scenario
    6.1 Regulatory Landscape
          6.1.1 US
          6.1.2 Canada
          6.1.3 Europe
          6.1.4 Japan
          6.1.5 China
          6.1.6 India
          6.1.7 Australia
    6.2 Reimbursement Scenario in Global Market

7. Marketed Gene Therapies
    7.1 Neovasculgen
    7.2 Glybera
    7.3 Gendicine, Rexin-G, Oncorine
          7.3.1 Gendicine
          7.3.2 Rexin G
          7.3.3 Oncorine

8. Global Gene Therapy Market

9. Gene Therapy Market by Application
    9.1 Oncology
          9.1.1 Clinical Trials
          9.1.1 Prevalence
          9.1.3 Market Outlook
    9.2 Cardiovascular Diseases
          9.2.1 Clinical Trials
          9.2.2 Prevalence
          9.2.3 Market Outlook
    9.3 Infectious Diseases
          9.3.1 Clinical Trials
          9.3.2 Prevalence
          9.3.3 Market Outlook
    9.4 Neurological Diseases
          9.4.1 Clinical Trials
          9.4.2 Prevalence
          9.4.3 Market Outlook
    9.5 Genetic Diseases
          9.5.1 Clinical Trials
          9.5.2 Prevalence
          9.5.3 Market Outlook
    9.6 Others
          9.6.1 Clinical Trials
          9.6.2 Prevalence
          9.6.3 Market Outlook

10. Global Gene Therapy Market Size by Geography
      10.1 North America
      10.2 Europe
      10.3 Asia
      10.4 Rest of the World (RoW)

11. Competitive Landscape
      11.1 Strategies Adopted by Various Players
              11.1.1 Strategic Collaborations
              11.1.2 Acquisitions
              11.1.3 Funding & Investments
      11.2 Companies Progress in Gene Therapy In 2015

12. Key Players Analysis (Business Description, Clinical Pipeline, Recent Developments, Strengths & Weaknesses)
      12.1 Spark Therapeutics, LLC
      12.2 ViroMed Co. Ltd. dba VM BioPharma
      12.3 Advantagene Inc.
      12.4 Bluebird Bio
      12.5 Sanofi
      12.6 Vical Inc.
      12.7 Oxford BioMedica Plc
      12.8 Genethon
      12.9 uniQure N.V.
      12.10 Human Stem Cells Institute
      12.11 Shanghai Sunway Biotech Co. Ltd.
      12.12 Sibiono GeneTech Co. Ltd.